Abstract
Background: Nanoformulation strategies that render spatial placement and temporal delivery of drugs feasible, can be of utility in delivering the drug specifically to afflicted liver cells for greater therapeutic benefit. Receptor-based targeting is an excellent approach if the receptor is found exclusively on the cells to which drug needs to be delivered. Asialoglycoprotein receptors (ASGPR), mannose receptor, transferrin, glycyrrhetinic acid are some of the receptors selectively present on certain cell types within a liver.
Objective: This review gives a glimpse of comparison of active vs. passive liver targeting and summarizes the plethora of ligands and delivery systems reported in the literature for targeting the receptors. Design of a targeted delivery system requires a comprehensive understanding of the interaction of targeting ligand with the receptors as well as its behaviour within the system.
Discussion: The review highlights techniques like fluorescence correlation spectroscopy, confocal microscopy, flow cytometry and surface plasmon resonance as some in vitro tools that can aid in investigating the behaviour of targeted formulations with biological systems. The fate of delivery system via various endocytic mechanisms depending on the cell type has been outlined.
Conclusion: Finally, the review deals with clinical relevance of liver-targeted nanoformulations addressing the aspect of safety and toxicity in developing targeted nanoarchitectonics.
Keywords: Hepatic targeting, ASGPR, glycyrrhetinic acid receptors, liposomes, receptor kinetics, surface plasmon resonance, nanoparticle toxicity, clathrin-mediated endocytosis.
Graphical Abstract
Drug Delivery Letters
Title:Role of Nanomedicine in Hepatic Targeting- Deciphering Strategies with Molecular Insights and Preclinical Prospects
Volume: 8 Issue: 2
Author(s): Vivek Dhawan, Megha Marwah and Mangal Nagarsenker*
Affiliation:
- Department of Pharmaceutics, Bombay College of Pharmacy, Kalina, Santacruz (East), Mumbai-400098,India
Keywords: Hepatic targeting, ASGPR, glycyrrhetinic acid receptors, liposomes, receptor kinetics, surface plasmon resonance, nanoparticle toxicity, clathrin-mediated endocytosis.
Abstract: Background: Nanoformulation strategies that render spatial placement and temporal delivery of drugs feasible, can be of utility in delivering the drug specifically to afflicted liver cells for greater therapeutic benefit. Receptor-based targeting is an excellent approach if the receptor is found exclusively on the cells to which drug needs to be delivered. Asialoglycoprotein receptors (ASGPR), mannose receptor, transferrin, glycyrrhetinic acid are some of the receptors selectively present on certain cell types within a liver.
Objective: This review gives a glimpse of comparison of active vs. passive liver targeting and summarizes the plethora of ligands and delivery systems reported in the literature for targeting the receptors. Design of a targeted delivery system requires a comprehensive understanding of the interaction of targeting ligand with the receptors as well as its behaviour within the system.
Discussion: The review highlights techniques like fluorescence correlation spectroscopy, confocal microscopy, flow cytometry and surface plasmon resonance as some in vitro tools that can aid in investigating the behaviour of targeted formulations with biological systems. The fate of delivery system via various endocytic mechanisms depending on the cell type has been outlined.
Conclusion: Finally, the review deals with clinical relevance of liver-targeted nanoformulations addressing the aspect of safety and toxicity in developing targeted nanoarchitectonics.
Export Options
About this article
Cite this article as:
Dhawan Vivek , Marwah Megha and Nagarsenker Mangal *, Role of Nanomedicine in Hepatic Targeting- Deciphering Strategies with Molecular Insights and Preclinical Prospects, Drug Delivery Letters 2018; 8 (2) . https://dx.doi.org/10.2174/2210303108666171204160219
DOI https://dx.doi.org/10.2174/2210303108666171204160219 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunotherapy for Myeloproliferative Neoplasms (MPN)
Current Cancer Drug Targets Is Going for Cure in CML Targeting Aberrant Glycogen Synthase Kinase 3β?
Current Drug Targets MGBG in Combined Anticancer Chemotherapy
Letters in Drug Design & Discovery Annexins in the Central Nervous System: Are they Neuroprotective or Proapoptotic Agents?
Medicinal Chemistry Reviews - Online (Discontinued) Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Patents in miRNAs Biomarkers for Gastrointestinal Cancer Diagnostics
Recent Patents on Biomarkers Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design Nanoscale Functional Biomaterials for Cancer Theranostics
Current Medicinal Chemistry Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Trends in Cell-Based Electrochemical Biosensors
Current Medicinal Chemistry Network-Based Strategies Can Help Mono- and Poly-pharmacology Drug Discovery: A Systems Biology View
Current Pharmaceutical Design PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Current Medicinal Chemistry Small Molecule Aurora Kinases Inhibitors
Current Medicinal Chemistry The Histone Deacetylase SIRT6: At the Crossroads Between Epigenetics, Metabolism and Disease
Current Topics in Medicinal Chemistry Drug-Induced Hypokalaemia
Current Drug Safety Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Reduction in Ischemic Cerebral Infarction is Mediated through Golgi Phosphoprotein 3 and Akt/mTOR Signaling Following Salvianolate Administration
Current Neurovascular Research Editorial (Thematic Issue: Endoplasmic Reticulum Stress and Mitochondrial Dysfunction in Diseases: Molecular Targets)
Current Pharmaceutical Design Studies on Efficacy of a Novel 177Lu-Labeled Porphyrin Derivative in Regression of Tumors in Mouse Model
Current Radiopharmaceuticals